BioMed Research International

BioMed Research International / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 3579832 | 8 pages | https://doi.org/10.1155/2018/3579832

In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates

Academic Editor: Isabel Portugal
Received19 Feb 2018
Accepted04 Jun 2018
Published02 Jul 2018

Abstract

Objectives. Evaluating the activity of nineteen β-lactams in combination with different β-lactamase inhibitors to determine the most potent combination against Mycobacterium tuberculosis (MTB) in vitro. Methods. Drug activity was examined by drug susceptibility test with 122 clinical isolates from China. Mutations of blaC and drug targets ldtMt1, ldtMt2, dacB2, and crfA were analyzed by nucleotide sequencing. Results. Tebipenem (TBM) in combination with clavulanate (CLA) exhibited the highest anti-TB activity. The MIC of β-lactam antibiotics was reduced most evidently in the presence of CLA, compared to avibactam (AVI) and sulbactam (SUB). Eight polymorphism sites were identified in blaC, which were not associated with β-lactams resistance. Interestingly, one strain carrying G514A mutation in blaC was highly susceptible to β-lactams regardless of the presence of inhibitors. The transpeptidase encoding genes, ldtMt1, ldtMt2, and dacB2, harboured three mutations, two mutations, and one mutation, respectively, but no correlation was found between these mutations and drug resistance. Conclusion. The activity of β-lactams against MTB and different synergetic effect of β-lactamase inhibitors were indicated. TBM/CLA exhibited the most activity and has a great prospect in developing novel anti-TB regimen; however, further clinical research is warranted. Moreover, the resistance to the β-lactam antibiotics might not be conferred by single target mutation in MTB and requires further studies.

1. Introduction

Tuberculosis (TB) is a great threat to the global public health that caused an estimated 1.3 million deaths in 2016 [1]. Drug resistance has been a major obstacle in the progress of eliminating TB, especially due to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) MTB worldwide [24]. With the rising incidence of drug-resistant TB, the traditional first-line and second-line anti-TB drugs fail to fulfill the current needs of TB treatments. In such cases, developing novel drugs or drug regimens is urgent and necessary for effective control of TB. Although significant progress has been made in identification of several new anti-TB compounds, such as bedaquiline, delamanid, and pretomanid, which are in phase II or III trials [5, 6], long duration and high expenses lead to slow development of new drugs. Repurposing the currently used antibiotics may contribute to the development of novel anti-TB regimens.

β-lactams disrupt the cell wall biosynthesis of bacteria by preventing the formation of peptide cross-links between the adjacent polysaccharide chains in the peptidoglycan layer [7]. In Mycobacterium tuberculosis (MTB), two kinds of transpeptidase, the L,D-transpeptidase (mainly encoded by ldtMt1 and ldtMt2) and the D,D-transpeptidase (encoded by dacB2), catalyze the cell wall biosynthesis [8, 9]. The L,D-transpeptidase, which is responsible for the formation of over 80% transpeptide linkages (3→3 linkages) in MTB, is the target of carbapenems [1012]. The D,D-transpeptidase that mainly catalyzes the formation of 4→3 linkages is a kind of penicillin-binding proteins (PBPs), which can be inhibited by meropenem (MEM) [13].

The resistance to β-lactam antibiotics encompasses the activity of β-lactamases. Thousands of different β-lactamases have been identified in various environmental and pathogenic species of bacteria [14]. MTB is intrinsically resistant to β-lactams due to the expression of endogenous β-lactamase BlaC active against a broad spectrum of β-lactams. CLA, AVI, and SUB are β-lactamase inhibitors that inhibit the hydrolysis of β-lactams. Recent studies have reported that a combination of the β-lactams and β-lactamase inhibitors is effective against MTB in vitro and in vivo [1517]. The efficacy, safety, and tolerability of carbapenems, such as MEM, imipenem, and ertapenem (ETP), against MTB have been evaluated in several clinical studies [18]. Amoxicillin/clavulanate (AMX/CLA) combination has been evaluated to be efficient against MTB in vitro and is thus categorized into Group 5 anti-TB drugs by WHO [19, 20]. This suggests that combinations of β-lactams and β-lactamase inhibitors are prospective candidates in developing more effective treatment against TB.

In this study, to determine the most active and applicable combination of β-lactam and β-lactamase inhibitors, the in vitro anti-TB activity of nineteen β-lactams belonging to different subclasses either alone or in combination with different β-lactamase inhibitors was tested using drug susceptibility tests. A total of 122 MTB clinical isolates collected from China were used. Mutations in blaC and three main β-lactams targets, ldtMt1, ldtMt2, and dacB2, were analyzed to determine the relationship between drug target mutations and β-lactam resistance. In addition, T184A mutation in an unannotated gene, crfA, reported to confer carbapenem resistance in MTB was also detected.

2. Materials and Methods

2.1. Strains

A total of 122 identified clinical MTB isolates, including 47 susceptible (S), 64 MDR, and 11 XDR isolates, used in this study were collected from seven provincial TB hospitals of China in Beijing, Anhui, Fujian, Guizhou, Henan, Xinjiang, and Sichuan. All the strains were preserved in the strain bank of National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention.

2.2. β-Lactams and β-Lactamase Inhibitors

MEM was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Tebipenem, doripenem, biapenem, ertapenem, amoxicillin, ampicillin, methicillin, oxacillin, cloxacillin, nafcillin, dicloxacillin, piperacillin, cephalexin, cefuroxime, cefixime, cefpirome, aztreonam, and moxalactam and three β-lactamase inhibitors, CLA, AVI, and SUB, used in this study were purchased from MCE Co. (Monmouth Junction, NJ, USA) (Table 1).


ClassificationAgentGeneration

CarbapenemTebipenem
Meropenem
Doripenem
Biapenem
Ertapenem
PenicillinAmoxicillin
Ampicillin
Methicillin
Oxacillin
Cloxacillin
Nafcillin
Dicloxacillin
Piperacillin
CephalosporinCephalexinFirst generation
CefuroximeSecond generation
CefiximeThird generation
CefpiromeFourth generation
MonobactamAztreonam
OxacephemMoxalactam
β-lactamase inhibitorClavulanate
Avibactam
Sulbactam

2.3. Drug Susceptibility Test

Drug susceptibility test was performed by broth microdilution method using 96-well microplate. Briefly, a loop of MTB culture in the late log phase was fully ground and adjusted with saline to a cell density of 3 × 108 cells/mL (1 McFarland standard). The suspension was diluted 1 : 20 with 7H9 broth (Difco, Detroit, MI, USA) containing 10% OADC (BD, Franklin Lakes, NJ, USA). Six groups of serial twofold drug dilutions were prepared in the 7H9 broth containing either five different constant concentrations of each β-lactamase inhibitor or no inhibitor at all. The final reaction mix contained 100 μl of drug solution and equal volume of bacterial suspension in each well. The plates were sealed and incubated at 37°C for 7 days. Then the indicator (20 μl Alamar Blue mixed with 50 μl 5% Tween-80) was added to the drug-containing group when the drug-free control showed color change (blue to pink). The lowest drug concentration that inhibited the strain growth and prevented color change was recorded as the MIC value. Drug susceptibility tests for each strain were repeated twice.

The final concentrations of tebipenem ranged from 0.125 to 16 μg/ml, and for the other carbapenems, 0.25 to 32 μg/ml concentrations were tested in drug susceptibility tests. Ampicillin (AMP) and cefuroxime (CXM) were used at concentrations ranging from 0.5 to 64 μg/ml and the other chemicals were tested at concentrations ranging from 1 to 128 μg/ml. The final concentration of each β-lactamase inhibitor was 0.625 μg/ml, 1.25 μg/ml, 2.5 μg/ml, 5 μg/ml, and 10 μg/ml, respectively.

2.4. Polymerase Chain Reaction (PCR) and Sequencing

Genomic DNA was isolated from mycobacterial cultures by boiling method and was used for amplification of blaC, ldtMt1, ldtMt2, dacB2, and crfA by polymerase chain reaction (PCR). The primer sets and conditions for amplification are shown in Table 2. The PCR products were sequenced (TSINGKE Biological Technology, Beijing, China) and the gene polymorphisms were identified by aligning with the reference strain H37Rv (GenBank accession no. NC_000962) using MEGA 7.0 software.


PrimersSequence (5′-3′)PCR conditionsProduct length (bp)
(s)Annealing (°C, s)(s)

BlaC-FATGCGCAACAGAGGATTCGGTC3061, 3065924
BlaC-RCTATGCAAGCACACCGGCAACG
-FATGCGTCGAGTGGTTCGTTATC3058, 3055756
-RCTAGCCGACCACCTCAATGG
-FATGCCAAAGGTGGGGATTGC3059, 30901227
-RTTACGCCTTGGCGTTACCGGC
DacB2-FACCAGCAACTGCTGGATTTC3060, 30851196
DacB2-RCGTTGATGACCAACGTCTTC
CrfA-FACCCGGCTCACAGAGAATCG3060, 3040457
CrfA-RTATCACCGGTAGGCCATGC

Note: denaturation temperature was 94°C; elongation temperature was 72°C. All PCRs were performed for 31 cycles and each reaction was initialized by denaturation at 94°C for 10 min and terminated with a final elongation step at 72°C for 10 min.

3. Results

3.1. Determination of Inhibitors’ Concentrations

The effective concentration of each β-lactamase inhibitor was determined by drug susceptibility tests against six MTB clinical isolates with nineteen β-lactams either alone or in combination with five different concentrations of β-lactamase inhibitors. The results showed that the MICs did not change when 5 μg/ml concentration of inhibitors was used (Table 3). Thus, we decided to use inhibitors at a fixed final concentration of 5 μg/ml in the subsequent experiments. All the carbapenems, AMX, ampicillin (AMP), and cefuroxime (CXM) were selected to perform further tests, because the other β-lactams showed no activity against MTB in the initial screening.


InhibitorsConcentrationMIC range (μg/ml)
TBMMEMDORBIAETPAMXAMPMETOXACLONAFDICPIPLEXCXMCFMCPOATMMOX

Clavulanate08-1616-328-168-1632->3264->128>64>128128->128>128>128>128>12864->128>64>12864->128>128>128
0.625<1-24-88-168-1616-3216-3232-64128->128128->128128->128>128>128>12864->12832->64>12864->128>128>128
1.25<144-84-816-328-3216-6464->128128->128128->128>128>128>12832->12816-64>12832->128>128>128
2.5<12-44-82-48-324-324-6432->12864->128128->128>128>128>12832->12816-32>12832->128>128>128
5<12-42-41-28-164-8<1-3216->12832->12864->12864->128>12864->12816->1284-16>12816->128>128>128
10<12-42-41-28-164-8<1-3216->12832->12864->12864->128>12864->12816->1284-16>12816->128>128>128
Avibactam08-1616-328-168-1632->3264->128>64>128128->128>128>128>128>12864->128>64>12864->128>128>128
0.6254-88-168-168-1616->3264-12832-64128->128128->128128->128>128>128>12832->12832->64>12832->128>128>128
1.252-48-164-168-1616-3232-12816-64128->128128->128128->128>128>128>12832->12832-64>12832->128>128>128
2.5<1-48-164-84-88-3232-648-6464->12864->128128->128>128>128>12832->12816-32>12832->128>128>128
5<1-24-162-42-48-168-328-3232->12864->128128->12864->128>128>12832->1288-32>12832->128>128>128
10<1-24-162-42-48-168-324-3232->12864->128128->12864->128>128>12832->1288-32>12832->128>128>128
Sulbactam08-1616-328-168-1632->3264->128>64>128128->128>128>128>128>12864->128>64>12864->128>128>128
0.6258-1616-328-168-1632->3264->12832-64128->128128->128>128>128>128>12832->12832->64>12832->128>128>128
1.254-1616-328-164-1616-3264->12816-6464->12864->128128->128>128>128>12832->12832-64>12832->128>128>128
2.54-816-324-164-816-3232->1288-6432->12864->128128->12864->128>128>12832->12816-32>12832->128>128>128
52-88-324-82-88-3216->644-6416->12832->128128->12864->128>128>12832->1288-32>12832->128>128>128
102-88-324-82-88-3216->644-6416->12832->12864->12864->128>128>12832->1288-32>12832->128>128>128

Note: TBM, tebipenem; MEM, meropenem; DOR, doripenem; BIA, biapenem; ETP, ertapenem; AMX, amoxicillin; AMP, ampicillin; MET, methicillin; OXA, oxacillin; CLO, cloxacillin; NAF, nafcillin; DIC, dicloxacillin; PIP, piperacillin; LEX, cephalexin; CXM, cefuroxime; CFM, cefixime; CPO, cefpirome; ATM, aztreonam; MOX, moxalactam.
3.2. MIC Profiles of β-Lactams against Clinical Isolates

The MIC profiles of the clinical isolates are shown in Table 4. In the case of carbapenems, TBM and biapenem (BIA) showed better activity with MIC90 of 16 μg/ml when they were used alone. The MICs of carbapenems were greatly reduced (4-8 folds), except for ETP (1-4 folds), in the presence of β-lactamase inhibitors. TBM in combination with CLA showed the most inhibitory activity with MIC50 and MIC90 of 1 μg/ml and 2 μg/ml, respectively, followed by BIA (2 μg/ml and 4 μg/ml) and doripenem (DOR) (2 μg/ml and 8 μg/ml). MEM in combination with CLA also exhibited good activity with MIC50 and MIC90 of 2 μg/ml and 8 μg/ml, respectively, but it was lower than that of TBM and BIA. ETP in combination with any of the inhibitors showed the least activity with MIC90 of >16 μg/ml. In the case of penicillins and cephalosporins, AMX/CLA showed highest activity against MTB with MIC50 and MIC90 of 2 μg/ml and 8 μg/ml, respectively, followed by AMP/CLA (4 μg/ml and 16 μg/ml). CXM alone or in combination with any of the inhibitors showed no anti-TB activity even when the highest drug concentration was tested.


AntibioticInhibitorMIC range (μg/ml)MIC50 (μg/ml)MIC90 (μg/ml)

TBMNone0.5->16816
CLA0.125->1612
AVI0.125->1612
SUB0.5->1624
BIANone2->32816
CLA0.25->3224
AVI0.5->3224
SUB0.5->3248
DORNone2->321616
CLA0.5->3228
AVI0.5->3248
SUB0.5->32416
MEMNone4->32>32>32
CLA0.25->3228
AVI1->32416
SUB4->32816
ETPNone8->32>32>32
CLA2->32816
AVI4->32816
SUB4->321632
AMXNone8->64>64>64
CLA<0.5-3228
AVI<0.5-64816
SUB2->64832
AMPNone32->6464>64
CLA0.5->64416
AVI0.5->64816
SUB0.5->641632
CXMNone16->64>64>64
CLA1->6432>64
AVI2->6432>64
SUB4->6464>64

Note: MIC50/90, MICs that inhibit 50% and 90% of the isolates, respectively.

Comparison of the synergistic effect of the three different β-lactamase inhibitors shows that CLA exhibited the most potent activity in inhibiting the β-lactamase. Overall, the MICs of β-lactams were reduced most prominently (4-32 folds) in the presence of CLA, followed by AVI (4-8 folds). However, the least activity was observed in case of SUB as MIC50 and MIC90 of all the tested drug combinations with SUB showed lesser reduction (2-8 folds) than that in the presence of CLA and AVI, especially when used in combination with TBM, BIA, and AMP.

3.3. Relationship between Drug Target Mutation and Resistance

Since the β-lactamase BlaC, L,D-transpeptidase, and D,D-transpeptidase are potential targets of β-lactams, the encoding genes, including blaC, ldtMt1, ldtMt2, and dacB2, were analyzed to illustrate the role of drug target mutations in the emergence of the β-lactams resistance in MTB. In addition, mutation at position T184A in an unannotated protein encoding gene, crfA, which was earlier reported to confer carbapenem resistance in MTB [21], was also analyzed. Mutations in the five genes are shown in Table 5 and the MIC profiles of the mutant strains are listed in the supplementary materials. As observed, 16.4% (20/122) of clinical isolates carried 8 mutation sites in blaC. The silent mutation, C786T (11 isolates), was the most predominant mutation. Three nonsynonymous mutations, T333G, T492A, and G514A, were observed in blaC, while none of these mutations was related to β-lactam resistance. Interestingly, one strain, GZ10116, which carried G514A mutation, was highly susceptible to β-lactams irrespective of the presence of inhibitors.


GeneSubstitutionAmino acid changeNumber of mutants

blaCG183ALeu61Leu1
T333GSer111Arg3
C354TSer118Ser1
G486CAla162Ala1
T492APhe164Leu1
G514AGly172Ser1
C610TLeu204Leu1
C786TIle262Ile11
ldtMt1A111GPro37Pro1
G448AAla150Thr1
C659TAla220Val2
ldtMt2C594TGly198Gly1
A776GAsp259Gly4
dacB2T659ALeu220Gln4

There were 1, 1, and 2 strains harbouring A111G, G448A, and C659T mutations, respectively, on ldtMt1. 1 strain and 4 strains, respectively, harboured C594T and A776G mutation in ldtMt2. Only one strain, which harboured A776G mutation in ldtMt2, was resistant to all the combinations of β-lactams and inhibitors. However, we did not find any mutation associated with the β-lactam resistance in ldtMt2. Only one mutation, T659A, was found on dacB2 in four strains, but it was also not associated with the β-lactam resistance. In addition, the results showed that no mutation was detected in crfA among all the strains in our study. We also did not find any strain harbouring mutations in the blaC and transpeptidase genes simultaneously.

4. Discussion

Novel drugs or regimens are urgently needed due to the rise in the prevalence of multidrug-resistant TB worldwide. β-lactams are widely used and well-tolerated antibiotics used for controlling clinical Gram-positive and Gram-negative bacterial infections [22]. Recently, the combination of β-lactamase inhibitor and β-lactam was shown to be effective in restoring the potency of β-lactam against MTB [1517]. In the present study, nineteen commercially available β-lactams and three β-lactamase inhibitors were screened in vitro to identify the most potent combination against MTB. The results show that carbapenems, except for ETP, exhibited excellent activity against MTB clinical strains. This may be due to the inactivation of multiple enzymes by carbapenems, whereas the other β-lactams did not inhibit the L,D-transpeptidase in MTB [10]. The activity of AMX was also improved notably in the presence of clavulanate. While the efficacy of AMX/CLA against clinical TB remains controversial, carbapenems may serve as an optimal alternative in developing novel anti-TB regimens. The results showed that all the tested cephalosporins in our study were inactive against MTB. Dincer et al. [23] reported that cefazolin in combination with CLA was active against H37Ra. This may be due to the different strain tested and different methodology used. Additionally, the concentration of CLA, that is, 32 μg/ml, was much higher than the concentration (5 μg/ml) used in our test. This suggests that a more universal drug susceptibility testing protocol for determining the MIC of β-lactams against MTB is needed in the future.

Carbapenems displayed a variable activity in this study. TBM in combination with CLA exhibited the highest activity against MTB, followed by BIA and DOR. MIC90 of TBM/CLA was 2 μg/ml, which can be easily obtained in plasma with the administration of a single dose of 200 mg TBM pivoxil granules [24]. Comparable activity to that of TBM/CLA was observed in case of BIA/CLA. The maximum plasma concentration () of BIA after a single intravenous dose was 17.4 μg/ml [25], which exceeded MIC90 (2 μg/ml) of BIA/CLA. Both of BIA and TBM are stable against renal dehydropeptidase-I and are also safe for central nervous system, since they do not exhibit competitive binding to the γ-aminobutyric acid (GABA) receptors [26]. However, BIA requires intravenous administration that is not easily complied with by the patients. MEM/CLA was previously reported to be effective against MDR-TB. The and AUC values of MEM were 26 μg/ml and 27.2–32.4 μg·h/ml, respectively, after being administered by an intravenous infusion of 500 mg of MEM [27]. In our results also, MEM/CLA exhibited potent activity (MIC90, 8 μg/ml) against MTB but it was weaker than that of TBM/CLA, which is consistent with previous study [28]. This may be explained by lower and less breakdown of the covalent tebipenem-BlaC adduct, in contrast to that of MEM, thus suggesting a higher activity of TBM against MTB [17, 29]. Oral administration of the TBM pivoxil had a better protective effect than meropenem in all the tried sepsis models, due to its greater tissue distribution [30]. Hence, as an oral carbapenem, TBM may be a better option in developing new anti-TB regimen.

MTB harbours a chromosomally encoded β-lactamase, which is selectively susceptible to β-lactamase inhibitors. In this study, varied synergistic effects of three different β-lactamase inhibitors were observed. Consistent with previous study [28], the greatest reduction in MIC was achieved by CLA in combination with β-lactams, especially in AMX/CLA (32-fold in MIC50). AVI, a newly developed β-lactamase inhibitor, combining with ceftazidime exhibited good activity against Enterobacteriaceae and Pseudomonas aeruginosa [31]. However, a combination of AVI with β-lactams displayed a lesser reduction in MIC of β-lactams compared to CLA. A recent report has demonstrated that the efficiency of AVI was lower than that of CLA due to its bulky rings that may influence its binding to BlaC [32]. The unstable covalent adduct of SUB and BlaC may also explain its lesser inhibiting activity than that of CLA [33]. Thus, CLA seems to be the most suitable in developing anti-TB regimens encompassing β-lactams. In addition, the concentration of 5 μg/ml of CLA used in the current study was lower than the of 5.9 μg/ml achieved after a 250 mg three times a day dosage, suggesting that it can be easily achieved in clinical use [34].

For investigating the relationship between mutations in the β-lactam targets and the drug susceptibility of MTB clinical isolates, blaC, ldtMt1, ldtMt2, and dacB2 in 122 MTB clinical isolates were sequenced and analyzed. BlaC hydrolyzes the β-lactam ring, which is essential for the activity of β-lactam antibiotics, resulting in the β-lactams resistance in MTB. Eight different mutations were observed in blaC. However, we did not find any association between these mutations and β-lactam resistance. Interestingly, one of the strains harbouring G514A (Gly172Ser) mutation was highly susceptible to β-lactam antibiotics in either the presence or the absence of the inhibitors. Zhang et al. [35] have reported that the S111R mutation on BlaC may be associated with an increased susceptibility of MTB. Considering that the mutation Gly172Ser may affect the interaction of BlaC and β-lactams [36], we may speculate that this amino change leads to a conformation change in BlaC, which influences its activity.

Mutation on target gene often confers drug resistance to bacteria. Four clinical MTB strains were found to carry mutation A776G in ldtMt2 and two of them were susceptible to β-lactams. Similarly, among the dacB2 mutants, one exhibited resistance, while the other exhibited susceptibility to β-lactams. However, we did not find any correlation between these mutations and the β-lactams resistance. In this study, we only tested four potential targets and none of the strains harboured mutations simultaneously on all the four genes. It is reported that the β-lactam antibiotics have to bind to at least three of the four identified PBPs to be effective [37]. Considering the multiple targets of β-lactams, we may speculate that the drug resistance may not be conferred by mutation in a single target. Further studies are required to demonstrate the role of drug target mutations in the development of β-lactam resistance in MTB in order to consider the inclusion of β-lactams in the anti-TB treatment regimens.

5. Conclusions

In summary, varied activities of carbapenems, penicillins, and cephalosporins alone or in combination with β-lactamase inhibitors against MTB were observed. TBM in combination with CLA showed the most remarkable activity and has a good prospect in developing novel anti-TB regimens. Further studies are warranted to investigate the efficacy of TBM/CLA in the clinical trials. Additionally, resistance to the β-lactams may not be conferred by single target mutation in MTB and thus requires further investigation.

Data Availability

The datasets used to support the findings of this study are available upon request from the corresponding author.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

Acknowledgments

This work was financially supported by the Key project of the State Key Laboratory for Infectious Disease Prevention and Control (2014SKLID104) and the project of the National Key Programs of Mega Infectious Diseases (2013ZX10003002-001).

Supplementary Materials

The details of mutations and the MIC profile of each mutant in this study are listed in the supplementary material file. (Supplementary Materials)

References

  1. World Health Organization, Global tuberculosis report, WHO Document, World Health Organization, 2017.
  2. L. Wang, H. Zhang, Y. Ruan et al., “Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data,” The Lancet, vol. 383, no. 9934, pp. 2057–2064, 2014. View at: Publisher Site | Google Scholar
  3. T. Cohen, H. E. Jenkins, C. Lu, M. McLaughlin, K. Floyd, and M. Zignol, “On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data,” Drug Resistance Updates, vol. 17, no. 4-6, pp. 105–123, 2014. View at: Publisher Site | Google Scholar
  4. K. Dheda, T. Gumbo, N. R. Gandhi et al., “Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis,” The Lancet Respiratory Medicine, vol. 2, no. 4, pp. 321–338, 2014. View at: Publisher Site | Google Scholar
  5. S. Tiberi, R. Buchanan, J. A. Caminero et al., “The challenge of the new tuberculosis drugs,” La Presse Médicale, vol. 46, no. 2, pp. e41–e51, 2017. View at: Publisher Site | Google Scholar
  6. A. Zumla, J. Chakaya, R. Centis et al., “Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies,” The Lancet Respiratory Medicine, vol. 3, no. 3, pp. 220–234, 2015. View at: Publisher Site | Google Scholar
  7. M. I. Page, “The Reactivity of β-Lactams, the Mechanism of Catalysis and the Inhibition of β-Lactamases,” Current Pharmaceutical Design, vol. 5, no. 11, pp. 895–913, 1999. View at: Google Scholar
  8. J.-L. Mainardi, R. Villet, T. D. Bugg, C. Mayer, and M. Arthur, “Evolution of peptidoglycan biosynthesis under the selective pressure of antibiotics in Gram-positive bacteria,” FEMS Microbiology Reviews, vol. 32, no. 2, pp. 386–408, 2008. View at: Publisher Site | Google Scholar
  9. M. Lavollay, M. Arthur, M. Fourgeaud et al., “The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation,” Journal of Bacteriology, vol. 190, no. 12, pp. 4360–4366, 2008. View at: Publisher Site | Google Scholar
  10. W.-J. Li, D.-F. Li, Y.-L. Hu, X.-E. Zhang, L.-J. Bi, and D.-C. Wang, “Crystal structure of L,D-transpeptidase in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis,” Cell Research, vol. 23, no. 5, pp. 728–731, 2013. View at: Publisher Site | Google Scholar
  11. J. F. Fisher and S. Mobashery, “beta-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis,” Cold Spring Harbor Perspectives in Medicine, vol. 6, no. 5, 2016. View at: Google Scholar
  12. V. Dubée, S. Triboulet, J.-L. Mainardi et al., “Inactivation of Mycobacterium tuberculosis L,D-transpeptidase by carbapenems and cephalosporins,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 8, pp. 4189–4195, 2012. View at: Publisher Site | Google Scholar
  13. P. Kumar, K. Arora, J. R. Lloyd et al., “Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis,” Molecular Microbiology, vol. 86, no. 2, pp. 367–381, 2012. View at: Publisher Site | Google Scholar
  14. C. Brandt, S. D. Braun, C. Stein et al., “In silico serine β-lactamases analysis reveals a huge potential resistome in environmental and pathogenic species,” Scientific Reports, vol. 7, p. 43232, 2017. View at: Publisher Site | Google Scholar
  15. P. Kumar, A. Kaushik, E. P. Lloyd et al., “Non-classical transpeptidases yield insight into new antibacterials,” Nature Chemical Biology, vol. 13, no. 1, pp. 54–61, 2017. View at: Publisher Site | Google Scholar
  16. A. Kaushik, N. C. Ammerman, R. Tasneen et al., “In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis,” Journal of Antimicrobial Chemotherapy, vol. 72, no. 8, pp. 2320–2325, 2017. View at: Publisher Site | Google Scholar
  17. J.-E. Hugonnet, L. W. Tremblay, H. I. Boshoff, C. E. Barry III, and J. S. Blanchard, “Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis,” Science, vol. 323, no. 5918, pp. 1215–1218, 2009. View at: Publisher Site | Google Scholar
  18. G. Sotgiu, L. D’Ambrosio, R. Centis et al., “Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: A systematic review,” International Journal of Molecular Sciences, vol. 17, no. 3, article no. 373, 2016. View at: Publisher Site | Google Scholar
  19. H. F. Chambers, T. Kocagöz, T. Sipit, J. Turner, and P. C. Hopewell, “Activity of amoxicillin/clavulanate in patients with tuberculosis,” Clinical Infectious Diseases, vol. 26, no. 4, pp. 874–879, 1998. View at: Publisher Site | Google Scholar
  20. P. R. Donald, F. A. Sirgel, A. Venter et al., “Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis,” Infectious Diseases, vol. 33, no. 6, pp. 466–469, 2001. View at: Publisher Site | Google Scholar
  21. P. Kumar, A. Kaushik, D. T. Bell et al., “Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 61, no. 3, Article ID e02234, 2017. View at: Publisher Site | Google Scholar
  22. O.-A. Abraham, V.-M. Rosa, S.-S. M. Antonio, G. Claudia, and M.-E. M. del Rosario, “Review of antibiotic and non-antibiotic properties of beta-lactam molecules,” Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, vol. 15, no. 1, pp. 3–14, 2016. View at: Publisher Site | Google Scholar
  23. I. Dinçer, A. Ergin, and T. Kocagöz, “The vitro efficacy of β-lactam and β-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis,” International Journal of Antimicrobial Agents, vol. 23, no. 4, pp. 408–411, 2004. View at: Publisher Site | Google Scholar
  24. M. Nakashima, J. Morita, and K. Aizawa, “Pharmakokinetics and safety of tebipenem pivoxil fidne granules, an oral carbapenem antibiotic, in healthy male volunteers,” Japanese Journal of Chemotherapy, vol. 57, no. 1, pp. 90–94, 2009. View at: Google Scholar
  25. C. M. Perry and T. Ibbotson, “Biapenem,” Drugs, vol. 62, no. 15, pp. 2221–2234, 2002. View at: Publisher Site | Google Scholar
  26. A. D. Miller, A. M. Ball, P. B. Bookstaver, E. K. Dornblaser, and C. L. Bennett, “Epileptogenic potential of carbapenem agents: Mechanism of action, seizure rates, and clinical considerations,” Pharmacotherapy, vol. 31, no. 4, pp. 408–423, 2011. View at: Publisher Site | Google Scholar
  27. G. G. Zhanel, R. Wiebe, L. Dilay et al., “Comparative review of the carbapenems,” Drugs, vol. 67, no. 7, pp. 1027–1052, 2007. View at: Publisher Site | Google Scholar
  28. Y. Horita, S. Maeda, Y. Kazumi, and N. Doi, “In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-Lactamase inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 11, pp. 7010–7014, 2014. View at: Publisher Site | Google Scholar
  29. S. Hazra, H. Xu, and J. S. Blanchard, “Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis,” Biochemistry, vol. 53, no. 22, pp. 3671–3678, 2014. View at: Publisher Site | Google Scholar
  30. R. Kobayashi, M. Konomi, K. Hasegawa, M. Morozumi, K. Sunakawa, and K. Ubukata, “In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 3, pp. 889–894, 2005. View at: Publisher Site | Google Scholar
  31. C. Pitart, F. Marco, T. A. Keating, W. W. Nichols, and J. Vila, “Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 6, pp. 3059–3065, 2015. View at: Publisher Site | Google Scholar
  32. H. Xu, S. Hazra, and J. S. Blanchard, “NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis,” Biochemistry, vol. 51, no. 22, pp. 4551–4557, 2012. View at: Publisher Site | Google Scholar
  33. J.-E. Hugonnet and J. S. Blanchard, “Irreversible inhibition of the Mycobacterium tuberculosisβ-lactamase by clavulanate,” Biochemistry, vol. 46, no. 43, pp. 11998–12004, 2007. View at: Publisher Site | Google Scholar
  34. A. R. White, C. Kaye, J. Poupard, R. Pypstra, G. Woodnutt, and B. Wynne, “Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an antimicrobial agent,” Journal of Antimicrobial Chemotherapy, vol. 53, supplement 1, pp. i3–i20, 2004. View at: Publisher Site | Google Scholar
  35. D. Zhang, Y. Wang, J. Lu, and Y. Pang, “In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis isolates,” Antimicrob Agents Chemother, vol. 60, no. 1, pp. 393–399, 2015. View at: Google Scholar
  36. L. W. Tremblay, F. Fan, and J. S. Blanchard, “Biochemical and structural characterization of Mycobacterium tuberculosisβ-lactamase with the carbapenems ertapenem and doripenem,” Biochemistry, vol. 49, no. 17, pp. 3766–3773, 2010. View at: Publisher Site | Google Scholar
  37. H. F. Chambers, D. Moreau, D. Yajko et al., “Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?” Antimicrobial Agents and Chemotherapy, vol. 39, no. 12, pp. 2620–2624, 1995. View at: Publisher Site | Google Scholar

Copyright © 2018 Fu Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1153 Views | 357 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.